Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 May 2019 | Story Igno van Niekerk | Photo Stephen Collett
Digital storytelling
Collaborating for the common good are from left: Willem Ellis, Karen Venter, Dr Deidre van Rooyen, Prof Hendri Kroukamp, Bishop Billyboy Ramahlele, and Dr Johan van Zyl.

Prof Hendri Kroukamp, Dean of the Faculty of Management Sciences quoted the Cat Stevens song I can’t keep it in, to capture the excitement surrounding the opening of a Digital Storytelling Lab on the Bloemfontein Campus on 10 May 2019.

After months of hard work by Dr Deidre van Rooyen, Willem Ellis, Karen Venter, as well as the staff of the University of the Free State’s (UFS) Centre for Development Support, the Common Good First lab was completed just in time for the launch attended by about 50 delegates from other South African universities, as well as private and public institutions.

Stories meet technology

In a message, from Prof Puleng LenkaBula, Vice-Rector: Institutional Change, Student Affairs, and Community Engagement, informed the audience that the launch heralded the joining of the old world of stories with the new world of digital technology. Julie Adair, Director of Digital Collaboration at Glasgow Caledonian University, Scotland, welcomed the UFS as a partner to this international social innovation collaborative project in a video message. 

Dr Van Rooyen, the project manager for the UFS, explained how she got involved in the Common Good First project, what the benefits of digital storytelling are, as well as what opportunities the lab creates for cooperation between role players involved in social innovation projects. 

Why the Common Good First lab?

The purpose of the lab is to create a digital network to identify, showcase and connect social innovation projects in South Africa to one another and to universities around the world for research, student engagement and learning and teaching. The lab has been fitted with state-of-the-art equipment for recording and digitising the stories that result from social innovation projects.

In a live Skype session with Dr Il-Haam Petersen, Postdoctoral Research Fellow at the Human Sciences Research Council (HSRC), and some of the recent successes of the digital stories in Philippi in the Western Cape were shared.

Bishop Billyboy Ramahlele, UFS Director Community Engagement did the final honours by cutting the ribbon, declaring the lab open, and sharing the dream that the work done in this lab will contribute to positive relationships and cooperation between the university and the community, in making not only the university, but the country and the world a better place.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept